

Review Article

Diabetes and the Brain: Oxidative Stress, Inflammation, and Autophagy

María Muriach,^{1,2} Miguel Flores-Bellver,¹ Francisco J. Romero,¹ and Jorge M. Barcia¹

¹ *Facultad de Medicina y Odontología, Universidad Católica de Valencia, Calle Quevedo 2, 46001 Valencia, Spain*

² *Facultad de Ciencias de la Salud, Universitat Jaume I, 12071 Castellón, Spain*

Correspondence should be addressed to Francisco J. Romero; fj.romero@ucv.es

Received 3 December 2013; Revised 30 July 2014; Accepted 30 July 2014; Published 24 August 2014

Academic Editor: Robb E. Moses

Copyright © 2014 María Muriach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes mellitus is a common metabolic disorder associated with chronic complications including a state of mild to moderate cognitive impairment, in particular psychomotor slowing and reduced mental flexibility, not attributable to other causes, and shares many symptoms that are best described as accelerated brain ageing. A common theory for aging and for the pathogenesis of this cerebral dysfunctioning in diabetes relates cell death to oxidative stress in strong association to inflammation, and in fact nuclear factor κ B (NF κ B), a master regulator of inflammation and also a sensor of oxidative stress, has a strategic position at the crossroad between oxidative stress and inflammation. Moreover, metabolic inflammation is, in turn, related to the induction of various intracellular stresses such as mitochondrial oxidative stress, endoplasmic reticulum (ER) stress, and autophagy defect. In parallel, blockade of autophagy can relate to proinflammatory signaling via oxidative stress pathway and NF κ B-mediated inflammation.

1. Introduction

Diabetes mellitus is a common metabolic disorder which is associated with chronic complications such as nephropathy, angiopathy, retinopathy, and peripheral neuropathy. However, as early as 1922 it was recognised that diabetes also can lead to cognitive dysfunction [1]. Since then, studies in experimental models and in patients observed alterations in neurotransmission, electrophysiological and structural abnormalities, and neurobehavioral alterations, in particular cognitive dysfunction and increased risk of depression [2]. Moreover, the observed cerebral manifestations of diabetes appear to develop insidiously, largely independent of diabetes-associated acute metabolic and vascular disturbances (such as severe hypo- and hyperglycemic episodes and stroke). Although the magnitude of these cognitive deficits appears to be mild to moderate, they can significantly hamper daily functioning, adversely affecting quality of life [3].

In spite of this, the concept of central neuropathy has been controversial for more than 80 years now, but while trying to describe cognitive impairment in diabetes as a complication of the disease, the term “diabetic encephalopathy” was

introduced in 1950 [4]. However, this term “encephalopathy” has not been widely accepted, probably among other reasons, because it does not seem to match with the mild cognitive problems usually seen in (nondemented) diabetic patients. More recently it has been suggested that the term “diabetes-associated cognitive decline” (DACD) describes a state of mild to moderate cognitive impairment, in particular psychomotor slowing and reduced mental flexibility, not attributable to other causes [5]. In addition, it is now clear that diabetes increases the risk of Alzheimer’s disease, vascular dementia, and any other type of dementia [6, 7].

2. Pathophysiological Mechanisms Involved in Brain Damage in Diabetes

Long-term effects of diabetes on the brain are manifested at structural, neurophysiological, and neuropsychological level, and multiple pathogenic factors appear to be involved in the pathogenesis of the cerebral dysfunctioning in diabetes, such as the hypoglycemic episodes, cerebrovascular alterations, the role of insulin in the brain, and the mechanisms of hyperglycemia induced damage [8]. Moreover, the emerging

view is that the diabetic brain features many symptoms that are best described as accelerated brain ageing [9].

A common theory, for aging and for the pathogenesis of this cerebral dysfunctioning in diabetes, relates cell death to oxidative stress mediated by free radicals [10]. Thus, hyperglycemia reduces antioxidant levels and concomitantly increases the production of free radicals. These effects contribute to tissue damage in diabetes mellitus, leading to alterations in the redox potential of the cell with subsequent activation of redox-sensitive genes [11].

The brain is especially vulnerable to oxidative damage as a result of its high oxygen consumption rate, abundant lipid content, and relative paucity of antioxidant enzymes as compared to other tissues. Neuronal cells are particularly sensitive to oxidative insults, and therefore reactive oxygen species (ROS) are involved in many neurodegenerative processes such as diabetes [12–14]. Although under normal physiological conditions a balance exists between the production of ROS and the antioxidant mechanisms, it has been shown that in aging tissues oxidative stress increases due to, among others, decreased activity of antioxidant enzymes [15]. Earlier work and ample evidence have shown that peroxidative damage to lipid and protein occurs with the aging process and the products of these reactions accumulate in the brain with age [16–19].

Similarly, the activities of superoxide dismutase and catalase or glutathione peroxidase enzymes, involved in the antioxidant defense of the diabetic brain, are decreased [20–23]. However, the possible source of oxidative stress in brain injury also includes autoxidation of glucose, lipid peroxidation, and decreased tissue concentrations of low molecular weight antioxidants such as reduced glutathione (GSH) [24–27]. This alteration of glutathione levels may be related to an increased polyol pathway [28] activity as this leads to a depletion of NADPH which is necessary for the enzymatic reduction of oxidized glutathione.

Moreover, in these pathological conditions, cellular stress triggers mitochondrial oxidative damage, which may result in apoptosis and/or necrosis [29], and apoptosis induced by oxidative stress has been related to neurogenesis inhibition [30]. Thus, it has been described that DM leads to alterations in the mitochondrial electron transport chain; ROS formation, mitochondrial energy metabolism dysfunction, and oxidative stress are thus being recognized as the main players in diabetes-related complications [31]. In this sense, Cardoso et al. have shown that hippocampal mitochondria of streptozotocin (STZ)-induced diabetic rats presented higher levels of MDA together with an increased glutathione disulfide reductase activity and lower manganese superoxide dismutase (MnSOD) activity and glutathione-to-glutathione disulfide (GSH/GSSG) ratio. It also showed impaired oxidative phosphorylation system characterized by a decreased mitochondrial energization potential and ATP levels and higher repolarization lag phase [32]. On the other hand, although insulin is best known for its involvement in the regulation of glucose metabolism in peripheral tissues, this hormone also affects numerous brain functions including cognition, memory, and synaptic plasticity through complex insulin/insulin receptor (IR) signaling pathways [33].

Therefore, considering the important role of insulin in many aspects of neuronal function in both the peripheral nervous system and the central nervous system, it is possible that perturbation of insulin signaling (both insulin deficiency in T1 diabetes and hyperinsulinemia in T2 diabetes) is in the pathogenesis of neurological diseases [34] and results in neurodegeneration.

Until recently, the study of insulin resistance was mainly focused on metabolic tissues such as muscle and adipose tissue; recent data, however, suggest that insulin resistance also develops in the nervous system. Although neurons are not insulin-dependent, they are insulin-responsive [35]. Insulin receptors are widely expressed in the brain, including the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, and amygdala. Insulin resistance in sensory neurons makes cells respond inappropriately to growth factor signals, and this impairment may contribute to the development of neurodegeneration and subsequent diabetic neuropathy. Moreover, insulin regulates mitochondrial metabolism and oxidative capacity through PI3K/Akt signaling [36, 37]; therefore, decreased Akt signaling by hyperinsulinemia-mediated IR may have profound effects on mitochondrial function in neurons and result in subsequent increased oxidative stress [38]. In fact, two of the leading theories that have emerged to explain insulin resistance center on mitochondrial function/dysfunction, although interestingly with opposite views. In one theory, inherited or acquired mitochondrial dysfunction is thought to cause an accumulation of intramyocellular lipids that lead to insulin resistance and implies that strategies to accelerate flux through β -oxidation should improve insulin sensitivity [39]. In the second theory, the impact of cellular metabolic imbalance is viewed in the context of cellular and mitochondrial bioenergetics, positing that excess fuel relative to demand increases mitochondrial oxidant production and emission, ultimately leading to the development of insulin resistance. In this case, elevated flux via β -oxidation in the absence of added demand is viewed as an underlying cause of the disease. Therefore, mitochondrial-derived oxidative stress is fairly well established as an underlying mechanism responsible for the pathological complications associated with diabetes [40], but it also has a role as a primary factor in the development of insulin resistance (and subsequent overt diabetes), since strong experimental evidence from various animal models utilizing mitochondrial targeted approaches has established a link between mitochondrial-derived ROS and insulin resistance in vivo [41, 42].

In conclusion, convincing evidence is now available from previous studies to prove the role of oxidative stress in the development of neuronal injury in the diabetic brain and the beneficial effects of antioxidants. More concretely, the beneficial effect of lutein and DHA in the brain of diabetic animals and the way that these substances were able to ameliorate the oxidative stress present in diabetes has been studied by our group [27, 43]. However, we must take into account, that there are also studies which report the lack of effect of antioxidants in diabetic complications. Thus, Je et al. [44] reported that vitamin C supplementation alone shows limited therapeutic benefit in type 1 diabetes and is more commonly used in combination with vitamin E or

other agents [44]. Moreover, most of the evidences favoring the increased oxidative stress in diabetes come from studies in experimental models of diabetes in which the degree of hyperglycemia is excessive. Supportive evidence is also available in studies of human subjects with diabetes; however interventional studies using select antioxidant supplements have failed to show significant benefits of supplementation, as reviewed by Hasanain and Mooradian [45]. The completion of some of the ongoing large clinical trials will shed additional light on the clinical merit of antioxidant supplementation.

3. Inflammation in Diabetes

Inflammation represents a fundamental biological process which stands as the foreground of a large number of acute and chronic pathological conditions, and this occurs in response to any alteration of tissue integrity in order to restore tissue homeostasis through the induction of various repair mechanisms. Proper regulation of these mechanisms is essential to prevent uncontrolled amplification of the initial inflammatory response and shift from tissue repair towards collateral damage and disease development [46].

The appropriate recognition of the danger by the host is primordial for the elaboration of proper adaptive responses. Sensing of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) is ensured by a complex set-up of pattern-recognition receptors (PRRs), which include, among others, the receptor for advanced glycation end-products (RAGE). PRR activation triggers a wealth of intracellular signaling pathways, including kinases (e.g., MAP kinases, PI3 kinase), adaptors, transcription factors (mainly nuclear factor- κ B (NF κ B)), and activator protein-1. Such signaling cascades foster the expression of cytokines, chemokines, enzymes, growth factors, and additional molecules that are required for tissue repair [47] and homeostasis restoration. However, there are situations in which such restoration may not adequately occur, resulting in persistent cellular stress, perpetuating and amplifying the inflammatory response. In these conditions, the process leads to significant alterations of tissue functions, with systemic and persistent derangements of homeostasis [48]. Diabetes and neurodegenerative diseases are typical examples of these pathological processes associated with such chronic inflammatory changes [49].

The release of reactive oxygen species has long been recognized as a typical consequence of immune cell stimulation [50, 51], and both acute and chronic inflammatory states are coupled with significant alterations of redox equilibrium, due to the associated enhancement of oxidant generation [49, 52–54]. Accordingly, mitigating oxidative stress by the use of antioxidants has been evaluated as a potentially useful anti-inflammatory strategy in such conditions, as recently reviewed [55]. Overall, the results of innumerable studies have clearly pointed out the strong association between oxidative stress and inflammation. Since responses triggered by Toll-like receptors (TLRs) are conveyed primarily by the activation of NF κ B, which is a master regulator of inflammation, controlling the expression of hundreds of

genes implicated in innate immune responses, and also a redox sensitive nuclear factor involved in the control of a large number of normal cellular and tissue processes, NF κ B has a strategic position at the crossroad between oxidative stress and inflammation.

NF κ B transcription factors are ubiquitously expressed in mammalian cells. These proteins are highly conserved across species, and in mammals the NF κ B family (also known as the Rel family) consists of five members: p50, p52, p65 (also known as RelA), c-Rel, and RelB. Rel family members function as dimers and the five subunits can homodimerize or heterodimerize. All family members share a Rel homology domain, which contains the crucial functional regions for DNA binding, dimerization, nuclear localization, and interactions with the I κ B inhibitory proteins. NF κ B dimers exist in a latent form in the cytoplasm bound by the I κ B inhibitory proteins, and when NF κ B-inducing stimuli activate the I κ B kinase complex that phosphorylates I κ B, this leads to its ubiquitination and subsequent degradation in the canonical NF κ B activation pathway. I κ B degradation exposes the DNA-binding domain and nuclear localization sequence of NF κ B and permits its stable translocation to the nucleus and the regulation of target genes [56]. Thus, activated NF κ B enters the nucleus to induce transcription of a myriad of genes that mediate diverse cellular processes such as immunity, inflammation, proliferation, apoptosis, and cellular senescence [57].

Together with the evidences that relate oxidative stress and inflammation to the pathophysiology of diabetes, studies performed in a variety of cell and animal based experimental systems also suggest that NF κ B activation is a key event early in the pathobiology of this disease and its complications [27, 58, 59]. In fact, several studies have highlighted the activation of NF κ B by hyperglycemia and its relationship with diabetic complications, as reviewed by Patel and Santani in 2009 [59]; thus, hyperglycemia triggers a number of mechanisms that are thought to underlie diabetic neuropathy. Studies in different experimental models have established that neuronal dysfunction is closely associated with the activation of NF κ B and the expression of proinflammatory cytokines [60, 61]. Moreover, NF κ B pathway has been revealed as a key molecular system involved in pathological brain inflammation [62], and also experimental studies [52] have suggested that neuronal apoptosis, which is related to NF κ B activation, may play an important role in neuronal loss and impaired cognitive function. Additionally, in the hippocampus of streptozotocin-treated rats, not only a strong increase in oxygen reactive species is observed but also a persistent activation of NF κ B is observed [23, 27]. Activated NF κ B can induce cytotoxic products that exacerbate inflammation and oxidative stress and promote apoptosis [63], leading to oxidative stress induced cell dysfunction or cell death, respectively [64]. However, it should not be forgotten that although NF κ B is widely known for its ubiquitous roles in inflammation and immune responses and in control of cell division and apoptosis (and these roles are apparent in the nervous system), neurons and their neighboring cells employ the NF κ B pathway for distinctive functions as well, ranging from the development to the coordination of cellular

responses to injury of the nervous system and to brain-specific processes such as the synaptic signaling that underlies learning and memory [60]. Therefore, understanding the function of NF κ B transcription factors in the nervous system is now a new frontier for the general field of NF κ B research, for the investigation of transcriptional regulation in complex neuronal systems, and for the understanding of pathological mechanisms of neurodegenerative diseases.

On the other hand, we cannot forget that type 2 (T2D) diabetes is an overnutrition related disease which usually is preceded by the metabolic syndrome, a common metabolic disorder that results from the increasing prevalence of obesity which includes several interconnected abnormalities such as insulin resistance, impaired glucose tolerance, dyslipidemia, and high blood pressure [65]. Moreover, overnutrition is considered as an independent environmental factor that is targeted by innate immune system to trigger an atypical form of inflammation, which leads to metabolic dysfunctions among others, in the central nervous system (CNS) and particularly in the hypothalamus [62, 66–69], which indeed is known to govern several metabolic functions of the body including appetite control, energy expenditure, carbohydrate and lipid metabolism, and blood pressure homeostasis [70, 71].

Deeping into the mechanisms that lead to this metabolic dysfunction, which also affects the CNS, it has been recently demonstrated that the activation of IKK β /NF κ B and consequently the proinflammatory pathway are a relevant feature in different metabolic disorders related to overnutrition [72–74]. The effects of NF κ B-mediated metabolic inflammation are deleterious and can give rise to impairments of normal intracellular signaling and disruptions of metabolic physiology [62] that have been reported also in the CNS—particularly in the hypothalamus—which primarily could account for the development of overnutrition-induced metabolic syndrome and related disorders such as obesity, insulin resistance, T2D, and obesity-related hypertension [68, 75, 76]. Moreover, intracellular oxidative stress and mitochondrial dysfunction seem to be upstream events that mediate hypothalamic NF κ B activation under overnutrition, and in turn such metabolic inflammation is reciprocally related to the induction of various intracellular stresses such as mitochondrial oxidative stress and endoplasmic reticulum (ER) stress [62]. Thus, intracellular oxidative stress seems to contribute to metabolic syndrome and related diseases, including T2D [39, 77, 78], and also to neurodegenerative diseases [79, 80]. In fact, when ROS homeostasis is disrupted, excessive ROS are accumulated in the mitochondria and cytoplasm and can cause oxidative damage to cells [81]. Regarding the ER, existing evidence also suggests that ER stress is a key link to obesity, insulin resistance, and type 2 diabetes [82], since this ER stress can also activate cellular inflammatory pathways which, in turn, impair cellular functions and lead to metabolic disorders [83] and neurodegenerative diseases [84, 85]. Indeed, unresolved ER stress can induce mitochondrial changes and finally cell apoptosis [86]. Moreover, brain ER stress is known to promote NF- κ B activation in the development of central metabolic dysregulations associated to inflammatory pathways, since intraventricular infusion of an ER stress

inhibitor suppressed the activation of hypothalamic NF κ B by high-fat diet feeding [68]. In addition, ER stress also appears to depend on IKK β /NF κ B pathway activity, because neither high-fat diet feeding nor central administration of chemical ER stress inducer is able to induce hypothalamic ER stress in mice with central inhibition of IKK β /NF κ B pathway [68, 87]. Finally, ER stress also causes cellular accumulation of ROS associated to oxidative stress [88], which in turn reciprocally can promote ER stress (see Figure 1).

In the case of ER stress, exposure to high glucose could induce ER stress by the generation of free radicals, aberrant protein glycosylation, or increased membrane and protein turnover. Zhang et al. have also reported that the expression of C/EBP homology protein (CHOP), the prominent mediator of the ER stress-induced apoptosis, was markedly increased in the hippocampus of diabetic rats and have suggested that this CHOP-ER stress-mediated apoptosis may be involved in hyperglycemia-induced hippocampal synapses and neuronal impairment and promote the diabetic cognitive impairment [89].

4. Autophagy and Diabetes

Autophagy plays a role in the maintenance of function of organelles such as mitochondria or ER [90, 91], in order to maintain a healthy and functional intracellular environment, cells must constantly clean up defective proteins (e.g., misfolded proteins overflowing from ER stress) or damaged organelles (e.g., dysfunctional mitochondria or ER from prolonged oxidative stress). Although, autophagy is known primarily as a prosurvival mechanism for cells facing stress conditions, accumulating evidence indicates that autophagy can contribute to cell death processes under pathological conditions [92, 93]. Thus, among others, autophagy defect has been linked to the development of metabolic syndrome, diabetes, alcoholism, and lipid abnormalities [94–96], and in the majority of these cases, the underlying pathogenesis is related to the failure of autophagy machinery to efficiently remove defective proteins or damaged organelles from the cytosol. In fact, chronic intracellular stress such as mitochondria or ER stress seems to be the critical upstream events, since animal studies have shown that in early stages ER stress or oxidative stress induce adaptive autophagy upregulation, helping to restore intracellular homeostasis by disposing a number of harmful molecules such as unfolded or misfolded proteins in ER lumen, cytosolic proteins damaged by ROS, or even dysfunctional ERs and mitochondria [97, 98]. However, when intracellular stresses remain unresolved, prolonged autophagy upregulation progresses into autophagy defect [62] and, in fact, the decreased efficiency of the autophagic system with age has gained renewed attention as a result of the increasing number of reports supporting a role for defective autophagy in the pathogenesis of different age-related diseases including diabetes among others [99]. In parallel, autophagy pathway can relate to proinflammatory signaling via oxidative stress pathway [100], since mitophagy/autophagy blockade leads to the accumulation of damaged, ROS-generating mitochondria, and this in turn




FIGURE 1: Scheme summarizing the involvement of oxidative stress (mitochondrial dysfunction and ER stress), inflammation, and autophagy in the diabetic brain. GSH: reduced glutathione; GSSG: glutathione disulfide; SOD: superoxide dismutase; NADP⁺: nicotinamide adenine dinucleotide phosphate oxidized; NADPH: nicotinamide adenine dinucleotide phosphate reduced; NAD⁺: nicotinamide adenine dinucleotide oxidized; NADH: nicotinamide adenine dinucleotide reduced; CAT: catalase; IκBa: nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells; ER: endoplasmic reticulum; GLUT: glucose; INS: insulin; P: phosphate; MDA: malondialdehyde; ATP: adenosine triphosphate; ETC: electron transport chain; ROS: reactive oxygen species; MnSOD: manganese superoxide dismutase; GSR: glutathione reductase; CHOP: C/EBP Homology Protein; TNFα: tumor necrosis factor alpha; NOS: nitric oxide synthases.

activates the NLRP3 inflammasome (a molecular platform activated upon signs of cellular “danger” to trigger innate immune defenses through the maturation of proinflammatory cytokines). Moreover, autophagy defect can induce NFκB-mediated inflammation [101, 102], even in the CNS, since Meng and Cai reported that defective hypothalamic autophagy led to hypothalamic inflammation, including the activation of proinflammatory IκB kinase β pathway [103].

Although it is clear that diabetes affects both mitochondria and ER, the role of autophagy in diabetes or metabolism is yet far from clear, and therefore the role of autophagy in the pathogenesis of diabetic complications is currently under intensive investigation.

As described by Hoffman et al., [104] specific candidates for induction and stimulation of autophagy include insulin deficiency/resistance [105, 106]; deficiency of insulin growth factor-1 (IGF-1) and insulin growth factor-1 receptor (IGF-1R) [104, 107]; hyperglucagonemia [106]; and hyperglycemia

[107]. Other candidates for perturbation of autophagy include alteration of protein synthesis and degradation [108] due to the oxidative stress of RNA [109, 110], protein damage, and altered lipid metabolism [94, 111]; increased production of ketones and aldehydes [112, 113]; and lipid peroxidation [110, 114]. Furthermore, accumulation of oxidized and glycated proteins, common protein modifications associated with diabetes, could be in part attributed to defective autophagy [115].

It is noteworthy that Hoffman et al. have reported that autophagy is increased in the brains of young T1D patients with chronic poor metabolic control and increased oxidative stress [116]. Moreover, the finding of significant expression of autophagic markers in both white and gray matter is in keeping with the structural deficits in young patients with T1D [117, 118] and the white matter atrophy in the frontal and temporal regions in these diabetic ketoacidosis cases [104]. However there are still few studies focusing on the role of

autophagy in the brains of T1D patients, and therefore further research is needed on the relationship between autophagy and pathogenesis of early onset diabetic encephalopathy in T1D.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] W. R. Miles and H. F. Root, "Root HF Psychologic tests applied in diabetic patients," *Archives of Internal Medicine*, vol. 30, pp. 767–770, 1922.
- [2] G. J. Biessels, A. C. Kappelle, B. Bravenboer, D. W. Erkelens, and W. H. Gispen, "Cerebral function in diabetes mellitus," *Diabetologia*, vol. 37, no. 7, pp. 643–650, 1994.
- [3] A. J. Sinclair, A. J. Girling, and A. J. Bayer, "Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services," *Diabetes Research and Clinical Practice*, vol. 50, no. 3, pp. 203–212, 2000.
- [4] R. N. De Jong, "The nervous system complications of diabetes mellitus, with special reference to cerebrovascular changes," *Journal of Nervous & Mental Disease*, vol. 111, no. 3, pp. 181–206, 1950.
- [5] G. S. Mijnhout, P. Scheltens, M. Diamant et al., "Diabetic encephalopathy: a concept in need of a definition," *Diabetologia*, vol. 49, no. 6, pp. 1447–1448, 2006.
- [6] G. J. Biessels, S. Staekenborg, E. Brunner, C. Brayne, and P. Scheltens, "Risk of dementia in diabetes mellitus: a systematic review," *The Lancet Neurology*, vol. 5, no. 1, pp. 64–74, 2006.
- [7] G. Cheng, C. Huang, H. Deng, and H. Wang, "Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies," *Internal Medicine Journal*, vol. 42, no. 5, pp. 484–491, 2012.
- [8] M. W. Brands, T. D. Bell, and B. Gibson, "Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide," *Hypertension*, vol. 43, no. 1, pp. 57–63, 2004.
- [9] G. J. Biessels, L. P. Van der Heide, A. Kamal, R. L. Bleys, and W. H. Gispen, "Ageing and diabetes: implications for brain function," *European Journal of Pharmacology*, vol. 441, no. 1–2, pp. 1–14, 2002.
- [10] K. B. Beckman and B. N. Ames, "The free radical theory of aging matures," *Physiological Reviews*, vol. 78, no. 2, pp. 547–581, 1998.
- [11] D. Bonnefont-Rousselot, "Glucose and reactive oxygen species," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 5, no. 5, pp. 561–568, 2002.
- [12] G. R. Jackson, K. Werrbach-Perez, Z. Pan, D. Sampath, and J. Perez-Polo, "Neurotrophin regulation of energy homeostasis in the central nervous system," *Developmental Neuroscience*, vol. 16, no. 5–6, pp. 285–290, 1994.
- [13] L. L. Dugan, S. L. Sensi, L. M. T. Canzoniero et al., "Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate," *The Journal of Neuroscience*, vol. 15, no. 10, pp. 6377–6388, 1995.
- [14] J. Yuan and B. A. Yankner, "Apoptosis in the nervous system," *Nature*, vol. 407, no. 6805, pp. 802–809, 2000.
- [15] K. Bala, B. C. Tripathy, and D. Sharma, "Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions," *Biogerontology*, vol. 7, no. 2, pp. 81–89, 2006.
- [16] W. Bondereff, "Histophysiology of the aging nervous system," *Advances in Gerontological Research*, vol. 18, pp. 1–22, 1964.
- [17] B. E. Wright and P. F. Davison, "Mechanisms of development and aging," *Mechanisms of Ageing and Development*, vol. 12, no. 3, pp. 213–219, 1980.
- [18] N. Z. Baquer, J. S. Hothersall, P. McLean, and A. L. Greenbaum, "Effect of aging on soluble and membrane bound enzymes in rat brain," *Neurochemistry International*, vol. 16, no. 3, pp. 369–375, 1990.
- [19] N. Sinha, A. Taha, N. Z. Baquer, and D. Sharma, "Exogenous administration of dehydroepiandrosterone attenuates loss of superoxide dismutase activity in the brain of old rats," *Indian Journal of Biochemistry and Biophysics*, vol. 45, no. 1, pp. 57–60, 2008.
- [20] J. S. Suresh Kumar and V. P. Menon, "Effect of diabetes on levels of lipid peroxides and glycolipids in rat brain," *Metabolism*, vol. 42, no. 11, pp. 1435–1439, 1993.
- [21] T. K. Makar, K. Rimpel-Lamhaouar, D. G. Abraham, V. S. Gokhale, and A. J. L. Cooper, "Antioxidant defense systems in the brains of type II diabetic mice," *Journal of Neurochemistry*, vol. 65, no. 1, pp. 287–291, 1995.
- [22] M. Miranda, M. Muriach, I. Almansa et al., "CR-6 protects glutathione peroxidase activity in experimental diabetes," *Free Radical Biology and Medicine*, vol. 43, no. 11, pp. 1494–1498, 2007.
- [23] R. Alvarez-Nölting, E. Arnal, J. M. Barcia, M. Miranda, and F. J. Romero, "Protection by DHA of early hippocampal changes in diabetes: possible role of CREB and NF- κ B," *Neurochemical Research*, vol. 37, no. 1, pp. 105–115, 2012.
- [24] L. P. Reagan, A. M. Magariños, D. K. Yee et al., "Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress," *Brain Research*, vol. 862, no. 1–2, pp. 292–300, 2000.
- [25] C. A. Grillo, G. G. Piroli, D. R. Rosell, E. K. Hoskin, B. S. McEwen, and L. P. Reagan, "Region specific increases in oxidative stress and superoxide dismutase in the hippocampus of diabetic rats subjected to stress," *Neuroscience*, vol. 121, no. 1, pp. 133–140, 2003.
- [26] N. N. Ulusu, M. Sahilli, A. Avci et al., "Pentose phosphate pathway, glutathione -dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E," *Neurochemical Research*, vol. 28, no. 6, pp. 815–823, 2003.
- [27] M. Muriach, F. Bosch-Morell, G. Alexander et al., "Lutein effect on retina and hippocampus of diabetic mice," *Free Radical Biology and Medicine*, vol. 41, no. 6, pp. 979–988, 2006.
- [28] A. Preet, B. L. Gupta, M. R. Siddiqui, P. K. Yadava, and N. Z. Baquer, "Restoration of ultrastructural and biochemical changes in alloxan-induced diabetic rat sciatic nerve on treatment with Na₃VO₄ and Trigonella: a promising antidiabetic agent," *Molecular and Cellular Biochemistry*, vol. 278, no. 1–2, pp. 21–31, 2005.
- [29] M. Merad-Boudia, A. Nicole, D. Santiard-Baron, C. Saillé, and I. Ceballos-Picot, "Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease," *Biochemical Pharmacology*, vol. 56, no. 5, pp. 645–655, 1998.
- [30] X. Cui, P. Zuo, Q. Zhang et al., "Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid,"

- Journal of Neuroscience Research*, vol. 84, no. 3, pp. 647–654, 2006.
- [31] P. I. Moreira, S. M. Cardoso, C. M. Pereira, M. S. Santos, and C. R. Oliveira, “Mitochondria as a therapeutic target in Alzheimer’s disease and diabetes,” *CNS and Neurological Disorders—Drug Targets*, vol. 8, no. 6, pp. 492–511, 2009.
 - [32] S. Cardoso, R. X. Santos, S. C. Correia et al., “Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance,” *Neurobiology of Disease*, vol. 49, no. 1, pp. 1–12, 2013.
 - [33] W. Q. Zhao and D. L. Alkon, “Role of insulin and insulin receptor in learning and memory,” *Molecular and Cellular Endocrinology*, vol. 177, no. 1-2, pp. 125–134, 2001.
 - [34] Q.-. Xu, X.-. Li, S. A. Kotecha, C. Cheng, H. S. Sun, and D. W. Zochodne, “Insulin as an *in vivo* growth factor,” *Experimental Neurology*, vol. 188, no. 1, pp. 43–51, 2004.
 - [35] A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri, “Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease,” *Endocrine Reviews*, vol. 30, no. 6, pp. 586–623, 2009.
 - [36] B. L. Stiles, “PI-3-K and AKT: onto the mitochondria,” *Advanced Drug Delivery Reviews*, vol. 61, no. 14, pp. 1276–1282, 2009.
 - [37] Z. Cheng, Y. Tseng, and M. F. White, “Insulin signaling meets mitochondria in metabolism,” *Trends in Endocrinology and Metabolism*, vol. 21, no. 10, pp. 589–598, 2010.
 - [38] K. H. Fisher-Wellman and P. D. Neuffer, “Linking mitochondrial bioenergetics to insulin resistance via redox biology,” *Trends in Endocrinology and Metabolism*, vol. 23, no. 3, pp. 142–153, 2012.
 - [39] B. B. Lowell and G. I. Shulman, “Mitochondrial dysfunction and type 2 diabetes,” *Science*, vol. 307, no. 5708, pp. 384–387, 2005.
 - [40] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.
 - [41] E. J. Anderson, M. E. Lustig, K. E. Boyle et al., “Mitochondrial H₂O₂ emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans,” *Journal of Clinical Investigation*, vol. 119, no. 3, pp. 573–581, 2009.
 - [42] K. L. Hoehn, A. B. Salmon, C. Hohnen-Behrens et al., “Insulin resistance is a cellular antioxidant defense mechanism,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 42, pp. 17787–17792, 2009.
 - [43] E. Arnal, M. Miranda, J. Barcia, F. Bosch-Morell, and F. J. Romero, “Lutein and docosahexaenoic acid prevent cortex lipid peroxidation in streptozotocin-induced diabetic rat cerebral cortex,” *Neuroscience*, vol. 166, no. 1, pp. 271–278, 2010.
 - [44] H. D. Je, C. Y. Shin, H. S. Park, I. H. Huh, and U. D. Sohn, “The comparison of vitamin C and vitamin E on the protein oxidation of diabetic rats,” *Journal of Autonomic Pharmacology*, vol. 21, no. 5, pp. 231–236, 2001.
 - [45] B. Hasanain and A. D. Mooradian, “Antioxidant vitamins and their influence in diabetes mellitus,” *Current Diabetes Reports*, vol. 2, no. 5, pp. 448–456, 2002.
 - [46] R. S. Goldszmid and G. Trinchieri, “The price of immunity,” *Nature Immunology*, vol. 13, no. 10, pp. 932–938, 2012.
 - [47] R. Medzhitov and T. Horng, “Transcriptional control of the inflammatory response,” *Nature Reviews Immunology*, vol. 9, no. 10, pp. 692–703, 2009.
 - [48] D. Okin and R. Medzhitov, “Evolution of inflammatory diseases,” *Current Biology*, vol. 22, no. 17, pp. R733–R740, 2012.
 - [49] P. Pacher, J. S. Beckman, and L. Liaudet, “Nitric oxide and peroxynitrite in health and disease,” *Physiological Reviews*, vol. 87, no. 1, pp. 315–424, 2007.
 - [50] B. Meier, H. H. Radeke, S. Selle et al., “Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor- α ,” *Biochemical Journal*, vol. 263, no. 2, pp. 539–545, 1989.
 - [51] B. Meier, H. H. Radeke, S. Selle et al., “Human fibroblasts release reactive oxygen species in response to treatment with synovial fluids from patients suffering from arthritis,” *Free Radical Research Communications*, vol. 8, no. 3, pp. 149–160, 1990.
 - [52] H. Li, S. Horke, and U. Förstermann, “Oxidative stress in vascular disease and its pharmacological prevention,” *Trends in Pharmacological Sciences*, vol. 34, no. 6, pp. 313–319, 2013.
 - [53] R. A. Roberts, R. A. Smith, S. Safe, C. Szabo, R. B. Tjalkens, and F. M. Robertson, “Toxicological and pathophysiological roles of reactive oxygen and nitrogen species,” *Toxicology*, vol. 276, pp. 85–94, 2010.
 - [54] L. Rochette, J. Lorin, M. Zeller et al., “Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?” *Pharmacology and Therapeutics*, vol. 140, no. 3, pp. 239–257, 2013.
 - [55] A. Spychalowicz, G. Wilk, T. Śliwa, D. Ludew, and T. J. Guzik, “Novel therapeutic approaches in limiting oxidative stress and inflammation,” *Current Pharmaceutical Biotechnology*, vol. 13, no. 13, pp. 2456–2466, 2012.
 - [56] M. K. Meffert and D. Baltimore, “Physiological functions for brain NF-kappaB,” *Trends in Neurosciences*, vol. 28, no. 1, pp. 37–43, 2005.
 - [57] S. Vaughan and P. S. Jat, “Deciphering the role of nuclear factor- κ B in cellular senescence,” *Aging*, vol. 3, no. 10, pp. 913–919, 2011.
 - [58] A. K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, and P. P. Nawroth, “The role of oxidative stress and NF- κ B activation in late diabetic complications,” *BioFactors*, vol. 10, no. 2-3, pp. 157–167, 1999.
 - [59] S. Patel and D. Santani, “Role of NF- κ B in the pathogenesis of diabetes and its associated complications,” *Pharmacological Reports*, vol. 61, no. 4, pp. 595–603, 2009.
 - [60] M. P. Mattson and S. Camandola, “NF- κ B in neuronal plasticity and neurodegenerative disorders,” *Journal of Clinical Investigation*, vol. 107, no. 3, pp. 247–254, 2001.
 - [61] A. M. Vincent, M. Brownlee, and J. W. Russell, “Oxidative stress and programmed cell death in diabetic neuropathy,” *Annals of the New York Academy of Sciences*, vol. 959, pp. 368–383, 2002.
 - [62] D. Cai and T. Liu, “Inflammatory cause of metabolic syndrome via brain stress and NF- κ B,” *Aging*, vol. 4, no. 2, pp. 98–115, 2012.
 - [63] H. L. Pahl, “Activators and target genes of Rel/NF- κ B transcription factors,” *Oncogene*, vol. 18, pp. 6853–6866, 1999.
 - [64] M. J. Morgan and Z. G. Liu, “Crosstalk of reactive oxygen species and NF-kappaB signaling,” *Cell Research*, vol. 21, pp. 103–115, 2011.
 - [65] R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” *The Lancet*, vol. 365, no. 9468, pp. 1415–1428, 2005.
 - [66] B. B. Kahn and J. S. Flier, “Obesity and insulin resistance,” *The Journal of Clinical Investigation*, vol. 106, pp. 473–481, 2000.
 - [67] S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity: modulation by nutrients and inflammation,” *The Journal of Clinical Investigation*, vol. 118, no. 9, pp. 2992–3002, 2008.
 - [68] X. Zhang, G. Zhang, H. Zhang, M. Karin, H. Bai, and D. Cai, “Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity,” *Cell*, vol. 135, pp. 61–73, 2008.

- [69] S. E. Shoelson and A. B. Goldfine, "Getting away from glucose: fanning the flames of obesity-induced inflammation," *Nature Medicine*, vol. 15, no. 4, pp. 373–374, 2009.
- [70] T. K. T. Lam, G. J. Schwartz, and L. Rossetti, "Hypothalamic sensing of fatty acids," *Nature Neuroscience*, vol. 8, no. 5, pp. 579–584, 2005.
- [71] B. Meister, "Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight," *Physiology & Behavior*, vol. 92, no. 1-2, pp. 263–271, 2007.
- [72] J. Sonoda, L. Pei, and R. M. Evans, "Nuclear receptors: decoding metabolic disease," *The FEBS Letters*, vol. 582, no. 1, pp. 2–9, 2008.
- [73] D. Cai, "NF-kappaB-mediated metabolic inflammation in peripheral tissues versus central nervous system," *Cell Cycle*, vol. 8, pp. 2542–2548, 2009.
- [74] C. N. Lumeng and A. R. Saltiel, "Inflammatory links between obesity and metabolic disease," *Journal of Clinical Investigation*, vol. 121, no. 6, pp. 2111–2117, 2011.
- [75] C. T. De Souza, E. P. Araujo, S. Bordin et al., "Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus," *Endocrinology*, vol. 146, no. 10, pp. 4192–4199, 2005.
- [76] B. F. Belgardt, J. Mauer, F. T. Wunderlich et al., "Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 13, pp. 6028–6033, 2010.
- [77] K. F. Petersen, D. Befroy, S. Dufour et al., "Mitochondrial dysfunction in the elderly: possible role in insulin resistance," *Science*, vol. 300, no. 5622, pp. 1140–1142, 2003.
- [78] H. S. Jung and M. S. Lee, "Role of autophagy in diabetes and mitochondria," *Annals of the New York Academy of Sciences*, vol. 1201, pp. 79–83, 2010.
- [79] M. T. Lin and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases," *Nature*, vol. 443, no. 7113, pp. 787–795, 2006.
- [80] M. K. Brown and N. Naidoo, "The endoplasmic reticulum stress response in aging and age-related diseases," *Frontiers in Physiology*, vol. 3, article 263, 2012.
- [81] E. Cadenas and K. J. A. Davies, "Mitochondrial free radical generation, oxidative stress, and aging," *Free Radical Biology and Medicine*, vol. 29, no. 3-4, pp. 222–230, 2000.
- [82] U. Özcan, E. Yilmaz, L. Özcan et al., "Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes," *Science*, vol. 313, no. 5790, pp. 1137–1140, 2006.
- [83] G. S. Hotamisligil, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease," *Cell*, vol. 140, no. 6, pp. 900–917, 2010.
- [84] I. Tabas and D. Ron, "Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress," *Nature Cell Biology*, vol. 13, no. 3, pp. 184–190, 2011.
- [85] Y. Meng, Y. Yong, G. Yang et al., "Autophagy alleviates neurodegeneration caused by mild impairment of oxidative metabolism," *Journal of Neurochemistry*, vol. 126, no. 6, pp. 805–818, 2013.
- [86] R. V. Rao, H. M. Ellerby, and D. E. Bredesen, "Coupling endoplasmic reticulum stress to the cell death program," *Cell Death and Differentiation*, vol. 11, no. 4, pp. 372–380, 2004.
- [87] S. Purkayastha, G. Zhang, and D. Cai, "Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB," *Nature Medicine*, vol. 17, pp. 883–887, 2011.
- [88] S. B. Cullinan and J. A. Diehl, "Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway," *International Journal of Biochemistry and Cell Biology*, vol. 38, no. 3, pp. 317–332, 2006.
- [89] X. Zhang, L. Xu, D. He, and S. Ling, "Endoplasmic reticulum stress-mediated hippocampal neuron apoptosis involved in diabetic cognitive impairment," *BioMed Research International*, vol. 2013, Article ID 924327, 9 pages, 2013.
- [90] S. Bernales, S. Schuck, and P. Walter, "ER-phagy: selective autophagy of the endoplasmic reticulum," *Autophagy*, vol. 3, no. 3, pp. 285–287, 2007.
- [91] S. Rodriguez-Enriquez, I. Kim, R. T. Currin, and J. J. Lemasters, "Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes," *Autophagy*, vol. 2, no. 1, pp. 39–46, 2006.
- [92] P. Wang and C. Miao, "Autophagy in the disorders of central nervous system: vital and/or fatal?" *CNS Neuroscience and Therapeutics*, vol. 18, no. 12, pp. 955–956, 2012.
- [93] K. Wei, P. Wang, and C. Miao, "A double-edged sword with therapeutic potential: an updated role of autophagy in ischemic cerebral injury," *CNS Neuroscience and Therapeutics*, vol. 18, no. 11, pp. 879–886, 2012.
- [94] R. Singh, S. Kaushik, Y. Wang et al., "Autophagy regulates lipid metabolism," *Nature*, vol. 458, no. 7242, pp. 1131–1135, 2009.
- [95] T. M. Donohue Jr., "Autophagy and ethanol-induced liver injury," *World Journal of Gastroenterology*, vol. 15, no. 10, pp. 1178–1185, 2009.
- [96] C. D. Gonzalez, M. Lee, P. Marchetti et al., "The emerging role of autophagy in the pathophysiology of diabetes mellitus," *Autophagy*, vol. 7, no. 1, pp. 2–11, 2011.
- [97] D. Butler and B. A. Bahr, "Oxidative stress and lysosomes: CNS-related consequences and implications for lysosomal enhancement strategies and induction of autophagy," *Antioxidants and Redox Signaling*, vol. 8, no. 1-2, pp. 185–196, 2006.
- [98] S. Matus, F. Lisbona, M. Torres, C. León, P. Thielen, and C. Hetz, "The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration," *Current Molecular Medicine*, vol. 8, no. 3, pp. 157–172, 2008.
- [99] E. Bergamini, G. Cavallini, A. Donati, and Z. Gori, "The role of macroautophagy in the ageing process, anti-ageing intervention and age-associated diseases," *International Journal of Biochemistry and Cell Biology*, vol. 36, no. 12, pp. 2392–2404, 2004.
- [100] R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation," *Nature*, vol. 469, pp. 221–225, 2011.
- [101] Y. Fujishima, S. Nishiumi, A. Masuda et al., "Autophagy in the intestinal epithelium reduces endotoxin-induced inflammatory responses by inhibiting NF- κ B activation," *Archives of Biochemistry and Biophysics*, vol. 506, no. 2, pp. 223–235, 2011.
- [102] T. O. Crişan, T. S. Plantinga, F. L. van de Veerdonk et al., "Inflammasome-independent modulation of cytokine response by autophagy in human cells," *PLoS ONE*, vol. 6, no. 4, Article ID e18666, 2011.
- [103] Q. Meng and D. Cai, "Defective hypothalamic autophagy directs the central pathogenesis of obesity via the I κ B kinase β (IKK β)/NF- κ B pathway," *The Journal of Biological Chemistry*, vol. 286, pp. 32324–32332, 2011.
- [104] W. H. Hoffman, A. V. Andjelkovic, W. Zhang, G. G. Passmore, and A. A. F. Sima, "Insulin and IGF-1 receptors, nitrotyrosin and

- cerebral neuronal deficits in two young patients with diabetic ketoacidosis and fatal brain edema,” *Brain Research*, vol. 1343, pp. 168–177, 2010.
- [105] E. J. Barrett, R. A. DeFronzo, S. Bevilacqua, and E. Ferrannini, “Insulin resistance in diabetic ketoacidosis,” *Diabetes*, vol. 31, no. 10, pp. 923–928, 1982.
- [106] C. M. Schworer and G. E. Mortimore, “Glucagon induced autophagy and proteolysis in rat liver: mediation by selective deprivation of intracellular amino acids,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 76, no. 7, pp. 3169–3173, 1979.
- [107] M. Liu, B. Spellberg, Q. T. Phan et al., “The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice,” *Journal of Clinical Investigation*, vol. 120, no. 6, pp. 1914–1924, 2010.
- [108] Q. Ding, E. Dimayuga, and J. N. Keller, “Oxidative stress alters neuronal RNA- and protein-synthesis: implications for neural viability,” *Free Radical Research*, vol. 41, no. 8, pp. 903–910, 2007.
- [109] R. J. Castellani, A. Nunomura, R. K. Rolston et al., “Sublethal RNA oxidation as a mechanism for neurodegenerative disease,” *International Journal of Molecular Sciences*, vol. 9, no. 5, pp. 789–806, 2008.
- [110] W. H. Hoffman, S. L. Siedlak, Y. Wang, R. J. Castellani, and M. A. Smith, “Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis,” *Brain Research*, vol. 1369, pp. 194–202, 2011.
- [111] D. S. Kim, S. K. Jeong, H. R. Kim, S. W. Chae, and H. J. Chae, “Effects of triglyceride on ER stress and insulin resistance,” *Biochemical and Biophysical Research Communications*, vol. 363, no. 1, pp. 140–145, 2007.
- [112] P. F. Finn and J. F. Dice, “Ketone bodies stimulate chaperone-mediated autophagy,” *Journal of Biological Chemistry*, vol. 280, no. 27, pp. 25864–25870, 2005.
- [113] B. G. Hill, P. Haberkzettel, Y. Ahmed, S. Srivastava, and A. Bhatnagar, “Unsaturated lipid peroxidation-derived aldehydes activate autophagy in vascular smooth-muscle cells,” *Biochemical Journal*, vol. 410, no. 3, pp. 525–534, 2008.
- [114] C. Muller, R. Salvayre, A. Nègre-Salvayre, and C. Vindis, “HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs,” *Cell Death and Differentiation*, vol. 18, no. 5, pp. 817–828, 2011.
- [115] M. Martinez-Vicente, G. Sovak, and A. M. Cuervo, “Protein degradation and aging,” *Experimental Gerontology*, vol. 40, no. 8-9, pp. 622–633, 2005.
- [116] W. H. Hoffman, J. J. Shacka, and A. V. Andjelkovic, “Autophagy in the brains of young patients with poorly controlled T1DM and fatal diabetic ketoacidosis,” *Experimental and Molecular Pathology*, vol. 93, no. 2, pp. 273–280, 2012.
- [117] A. M. Wessels, S. A. Rombouts, P. L. Remijnse et al., “Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume,” *Diabetologia*, vol. 50, no. 8, pp. 1763–1769, 2007.
- [118] T. Aye, A. L. Reiss, S. Kesler et al., “The feasibility of detecting neuropsychologic and neuroanatomic effects of type 1 diabetes in young children,” *Diabetes Care*, vol. 34, no. 7, pp. 1458–1462, 2011.